Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

No cookies to display.

Focus of the Report: This report focuses on annular closure for the prevention of recurrent lumbar disc herniation (LDH) after lumbar discectomy (LD).

Technology Description: Annular closure is a surgical treatment that is performed immediately following an LDH debridement surgery (e.g., lumbar discectomy, sequestrectomy, nucleotomy). The annular closure surgical procedure involves the implantation of a device to mimic healthy annulus fibrosus at the site of the annular defect in order to aid recovery and prevent future reherniation. The Barricaid annular closure device is currently the only Food and Drug Administration (FDA) approved method of annular closure that is available. The Barricaid annular closure device (ACD) is a U-shaped bone-anchored implantable device comprising a jagged titanium wing and a woven polyester fabric occlusion component. The ACD is implanted such that the occlusion component fills the void of the annular defect, and the titanium alloy arm anchors the ACD onto the adjacent vertebral body.

Controversy: LD is the standard surgery utilized to treat symptomatic LDH that is refractory to treatment with conservative care. While LD is an effective method of achieving symptom relief, it does not address the etiological cause of LDH, and leaves patients prone to recurrent LDH at the same weakened annular defect. Annular closure involves the insertion of a bone-anchored device into the annular defect to help contain the nucleus pulposus and reinforce the weakened annulus fibrosus, which could reduce postoperative recurrence and complications that are observed after stand-alone LD (Choy et al., 2018; Ammerman et al., 2019).

Key Questions:

  • Is annular closure an effective adjunct to lumbar discectomy (LD) for improving radiculopathy and preventing lumbar disc reherniation (LDH)?

  • How does adjunctive annular closure device (ACD) implantation surgery compare with traditional LDH surgical interventions performed without annular closure?

  • Is annular closure a safe adjunct to LD alone?

  • Have definitive patient selection criteria for annular closure been established?

If you have a Hayes login, click here to view the full report on the Knowledge Center.